GlassScriptPhysician profile
Sayed Tariq Rizvi
NPI 1114198348
$7,419.49
in general payments reported to CMS, 2019-2025
25 companies · $66.44 in 2025
The $66.44 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $199 · 2021: $265 · 2022: $1,406 · 2023: $1,143 · 2024: $3,998 · 2025: $66.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,798 · Food and Beverage: $1,410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,797.76 |
| Food and Beverage | $1,410.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,266.29 | 2021-2024 | Onyx Frontier, Symplicity G3 |
| Boston Scientific Corporation | $2,181.19 | 2019-2023 | |
| Abbott Laboratories | $748.00 | 2023-2024 | Mitraclip |
| E.R. Squibb & Sons, L.L.C. | $262.11 | 2023-2024 | Camzyos, Reblozyl |
| Janssen Pharmaceuticals, INC | $205.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $169.50 | 2019-2023 | |
| Medtronic Vascular, INC. | $109.89 | 2019-2020 | |
| Angiodynamics, INC. | $89.17 | 2021 | |
| Cumberland Pharmaceuticals, INC. | $73.74 | 2023 | Caldolor |
| Amgen INC. | $63.80 | 2019-2022 | |
| Stryker Corporation | $44.61 | 2025 | Omnicurve, Autoplex |
| Abiomed | $35.60 | 2024-2025 | Impella |
| Ge Healthcare | $21.38 | 2021 | |
| Shockwave Medical, INC | $21.10 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cvrx, INC. | $19.44 | 2024 | Barostim Neo System |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $18.00 | 2023 | Cardiohelp |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.56 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.77 | 2022 | |
| Siemens Medical Solutions USA, INC. | $11.76 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.48 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.32 | 2019 | |
| Pfizer INC. | $10.95 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sayed Tariq Rizvi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.